Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
News|Articles|January 23, 2026
- Vol.27/No.2
- Volume 27
- Issue 2
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
Author(s)Kyle Doherty
Fact checked by: Cheney Gazzam Baltz
Experts across tumor types share their insights on the notable FDA regulatory decisions of 2025.
Advertisement
Advertisement
In 2025, more than 60 agents and combinations, including biosimilars, earned accelerated, regular, or expanded approvals from the FDA, reshaping the treatment paradigms of multiple disease states and offering additional options for patients.
Related to this article
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
Advertisement
Advertisement